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Abstract
Background
Chronic migraine is a debilitating headache disorder that has significant impact on quality of
life. Stimulation of peripheral nerves is increasingly being used to treat chronic refractory
pain including headache disorders. This systematic review examines the effectiveness and
adverse effects of occipital nerve stimulation (ONS) for chronic migraine.
Methods
Databases, including the Cochrane Library, MEDLINE, EMBASE, CINAHL and clinical trial
registers were searched to September 2014. Randomized controlled trials (RCTs), other
controlled and uncontrolled observational studies and case series (n 10) were eligible.
RCTs were assessed using the Cochrane risk of bias tool. Meta-analysis was carried out
using a random-effects model. Findings are presented in summary tables and forest plots.
Results
Five RCTs (total n=402) and seven case series (total n=115) met the inclusion criteria.
Pooled results from three multicenter RCTs show that ONS was associated with a mean re-
duction of 2.59 days (95% CI 0.91 to 4.27, I2=0%) of prolonged, moderate to severe head-
ache per month at 3 months compared with a sham control. Results for other outcomes
generally favour ONS over sham controls but quantitative analysis was hampered by in-
complete publication and reporting of trial data. Lead migration and infections are common
and often require revision surgery. Open-label follow-up of RCTs and case series suggest
long-term effectiveness can be maintained in some patients but evidence is limited.
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Conclusions
While the effectiveness of ONS compared to sham control has been shown in multiple
RCTs, the average effect size is modest and may be exaggerated by bias as achieving ef-
fective blinding remains a methodological challenge. Further measures to reduce the risk of
adverse events and revision surgery are needed.
Systematic Review Registration
this systematic review is an update and expanded work of part of a broader review regis-
tered with PROSPERO. Registration No. CRD42012002633.
Introduction
Migraine is a debilitating primary headache disorder that has been ranked as the eighth leading
cause in terms of years lived with disability globally [1]. While most people with migraine have
‘episodic migraine’ (defined as having<15 days of headache each month), each year about
2.5% of the sufferers have their headache ‘transformed’ into chronic migraine [2], which has
even greater impact on the level of disability, social functioning and use of healthcare resources
compared to episodic migraine [3].
Chronic migraine is defined as “headache occurring on 15 or more days per month for
more than 3 months, which has the features of migraine headache on at least 8 days per
month” in the latest International Classification of Headache Disorders, 3rd edition beta ver-
sion (ICHD-III beta) [4]. An alternative term ‘transformed migraine’ which emphasises the na-
ture of headache that is developed from episodic migraine with increasing headache frequency
but decreasing severity of migraine features has also been used in the literature [5]. The diag-
nostic criteria and definitions for chronic migraine have been evolving over time with different
requirements regarding the number and feature of headache days and varied exclusion criteria
in relation to medication overuse headache [6]. Medication overuse headache refers to chronic
headache that is developed as a consequence of regular overuse of acute or symptomatic head-
ache medication such as paracetamol, anti-inflammatory drugs, ergotamine, triptans and opi-
oids [4]. It occurs commonly among migraine sufferers and is a risk factor contributing to the
development from episodic to chronic migraine. Medication withdrawal may revert chronic
migraine back to episodic migraine [3]. In ICHD-II, medication overuse needs to be absent for
a diagnosis of chronic migraine to be made [7], but a concomitant diagnosis of chronic mi-
graine and medication overuse headache is allowed in ICHD-III beta [4] and is indeed used in
common practice. As controversies over the optimal definition of chronic migraine are yet to
be resolved, we use the term ‘chronic migraine’ in the rest of this paper for consistency, but use
it to include chronic or transformed migraine in its various manifestations.
Treatments for chronic migraine aim to reduce the frequency of migraine attacks and asso-
ciated disability [3]. Many drugs for the prophylaxis of episodic migraine have been used
(often off-label) for chronic migraine [3]. Only topiramate and botulinum toxin type A are
supported by evidence from large randomised trials of patients with chronic migraine [3, 6, 8].
Despite the advances in the management of headache disorders, many patients with chronic
migraine remain refractory to current treatments—a recent study in a tertiary headache centre
in Spain showed that 15 of 20 patients with chronic migraine fulfilled the criteria for refractory
chronic migraine [9]. Novel treatments backed by good evidence are therefore in much need.
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Electrical stimulation of peripheral nerves has been used to treat various painful conditions
including headache disorders[10]. Occipital nerve stimulation (ONS) is one of the invasive
techniques that is gaining popularity for treating chronic migraine[11]. Continuous stimula-
tion of occipital nerves is achieved by the delivery of electrical impulses through cylindrical or
paddle electrodes (leads) implanted subcutaneously. The procedure is usually done in two
stages, involving an initial trial of stimulation of a few days to a couple weeks which, if success-
ful, is followed by a permanent implant [12].
ONS may have a plausible biological basis [13] and has been shown to affect blood flow in
brain structures thought to be important in the patho-physiology of migraine [14]. Early case
series in patients with chronic migraine were summarized in a systematic review and showed
promising results [15]. These were followed by randomized controlled trials (RCTs) reporting
mixed findings [16–19]. As these RCTs were not included the previous review and further case
series have been published, this systematic review aims to critically appraise this growing body
of evidence and provide an overview to inform clinical and policy decisions.
Methods
This systematic review was initially conducted as part of a broad review of evidence on the use
of invasive peripheral nerve stimulation for treating chronic refractory pain in support of the
development of Interventional Procedures Guidance by the UK National Institute for Health
and Care Excellence (NICE) [20]. The protocol for the broad review was registered with PROS-
PERO (Registration No. CRD42012002633). This paper reports an updated review focusing on
ONS for chronic migraine.
Search strategy and selection criteria
The following electronic databases were searched (inception to September 2014):
• The Cochrane Library (Wiley)
• MEDLINE and MEDLINE In Process (Ovid), EMBASE (Ovid) and CINAHL (EBSCO)
• The ZETOC (Mimas) database, and Conference Proceedings Citation Index (ISI Web of
Knowledge).
• Current Controlled Trials metaRegister, NIHR Clinical Research Network Portfolio, WHO
International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov for
ongoing studies.
Searches were conducted using index terms and key words relating to peripheral nerve stim-
ulation, chronic pain, headache disorders, migraine and occipital nerve stimulation. No lan-
guage restriction was applied. A sample search strategy can be found in Appendix A in S1 File.
Relevant websites including the Medicines and Healthcare Products Regulatory Agency
(MHRA) and Food and Drug Administration (FDA) were searched and reference lists of in-
cluded studies were scanned. Studies highlighted during NICE’s public consultation of relevant
Interventional Procedures Guidance were also examined.
At least two reviewers independently carried out the study selection. A study was included if it:
• Recruited patients with chronic migraine, defined according to the International Classifica-
tion of Headache Disorders, 2nd edition (ICHD-II)[7] or its subsequent modification [21].
Studies that adopted diagnostic criteria for transformed migraine suggested by Silberstein
and colleagues prior to ICHD-II were also included [5].
• Investigated the effect of stimulation of occipital nerves or areas innervated by them.
Occipital Nerve Stimulation for Chronic Migraine
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• Was an RCT or non-randomized controlled study, or an uncontrolled case series with at
least 10 patients.
• Reported results for chronic migraine separately where various types of headache disorders
were included.
We included studies in migraine patients where all participants were refractory to multiple
prophylactic treatments but the proportion of patients with chronic migraine (as oppose to epi-
sodic migraine) was not clearly reported. Non-English studies or those published only as con-
ference abstracts were excluded, with the exception of RCTs which were included irrespective
of publication status. Studies that focused on the combined use of ONS with other forms of
nerve stimulation were excluded.
Data extraction and assessment of risk of bias
Details on study design, trial participants, techniques of nerve stimulation, funding sources, ef-
fectiveness findings, and adverse events were extracted. For effectiveness, outcome measures
recommended by the International Headache Society’s guidelines were used [22].
The Cochrane Collaboration’s Risk of Bias Tool was used to appraise RCTs [23]. Informa-
tion regarding the effectiveness of blinding and patients’ expectation of treatment was also
noted. Data extraction and assessment of risk of bias was carried out by one reviewer and quali-
ty assured by another. Any discrepancies in study selection, extraction and assessment were re-
solved through discussions. Case series were used to provide supplementary evidence on
stimulation trials, adverse events and longer-term effectiveness. No separate risk of bias assess-
ment was carried out for them. The overall quality of evidence for selected key outcomes was
rated according to the GRADE framework [24].
Data synthesis
Characteristics of included studies and the results of risk of bias assessment were tabulated. As-
sessment of effectiveness focused on evidence from RCTs. Where suitable data was available
(see Appendix B in S1 File), meta-analyses of risk ratios (for binary outcomes) and mean differ-
ences (for continuous outcomes) were carried out in Review Manager 5.2 using a random-
effects model. Statistical heterogeneity between studies was evaluated by visual inspection of
forest plots and the I2 statistic. No statistical assessment of potential publication bias was car-
ried out due to the relatively small number of included RCTs. Authors and sponsors of partially
reported RCTs were contacted for unpublished data, although none were supplied.
As the majority of the adverse events were related to surgical procedures and implanted de-
vices (rather than to the stimulation per se), data concerning adverse events from the active
stimulation and sham control arms of the RCTs were combined (unless otherwise specified)
and presented alongside additional data from case series. The proportion of patients who expe-
rienced specific adverse events were displayed in forest plots with 95% confidence interval cal-
culated using the exact method [25]. Meta-analysis was not carried out for adverse events given
the varied methods of data collection, event classification and length of follow-up
between studies.
Results
Five RCTs (reported in nine publications [17–19, 26–31]) and seven case series [32–38] met
the inclusion criteria (Fig. 1). In addition, one unpublished [39] and one ongoing RCT [29]
was identified. The unpublished RCT (the UK PRISM study) was terminated early (with only
eight patients enrolled) based on interim data from another RCT [16] (PRISM study, included
Occipital Nerve Stimulation for Chronic Migraine
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in this review) sponsored by the same manufacturer. A list of excluded studies with reasons for
exclusion can be found in Appendix C in S1 File.
Characteristics of included studies
Of the five included RCTs (Table 1), three were industry-sponsored, multicentre, parallel-
group trials (PRISM study—published only as a conference abstract [16], ONSTIM study [17],
and Silberstein et al. 2012 [19]) and two were single-centre crossover trials (Serra and
Fig 1. Flow diagram for study selection.
doi:10.1371/journal.pone.0116786.g001
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Marchioretto 2012 [18], Slotty et al. 2014 [31]). The sample size ranged from 67 to 157 in the
multicentre RCTs and was eight and 30 for each of the two single centre RCTs respectively.
All three multicentre RCTs included an initial blinded phase of 12 weeks, during which pa-
tients received either active or sham stimulation.[16, 17, 19] The blinded phase was followed
by an open label phase of 1–3 years during which all participants received active stimulation
(results not yet published). The ONSTIM study also included a third arm of medication
Table 1. Characteristics of included randomized controlled trials.
Study, location
& sample size
(n randomized)
Centre, design &
treatment arms
(n analysed)*
Diagnostic
criteria
Treatment
history
Patients with
medication
overuse
Trial
stimulation
and/or nerve
block required
Follow-up Sponsorship &
comments
Lipton et al. 2009
(PRISM study),
[16] USA, n = 140
Multicentre,
parallel-group,
ONS (n = 63) vs.
sham (n = 62)
ICHD-2
(migraine with
or without aura,
and/or chronic
migraine)
Refractory to
 2 acute and
2
prophylactic
medications
Included (pre-
speciﬁed
subgroup)
Trial
stimulation
done but
success was
not an
inclusion
criteria
Double-blind 12
weeks,
uncontrolled open
label 1 year
Industry
sponsored;
published only as a
conference
abstract
Saper et al. 2011
(ONSTIM study),
[17] USA,
Canada & UK, n
= 67
Multicentre,
parallel-group,
ONS (n = 28) vs.
sham (n = 16) vs.
medication
management (n =
17)
ICHD-2 (chronic
migraine)
Refractory to
 2 classes of
prophylactic
medications
Excluded Successful
temporary
nerve block
(50%
reduction in
pain) required
Single-blind 12
weeks,
uncontrolled
open-label 3
years
Industry
sponsored; also
included an non-
randomized
ancillary arm (n =
8), in which
patients who did
not respond to
occipital nerve
block received
active ONS
Silberstein et al.
2012,[28, 30]
USA, n = 157
Multicentre,
parallel-group,
ONS (n = 105) vs.
sham (n = 52)
ICHD-2 (chronic
migraine) with
modiﬁcation
using the
Silberstein-
Lipton
diagnostic
criteria for
transformed
migraine
Refractory to
 2 acute and
2 classes of
prophylactic
medications
Possibly
included
(through the
criteria for
transformed
migraine)
Successful trial
stimulation
(50%
reduction in
pain or
adequate
paresthesia)
required
Double-blind 12
weeks,
uncontrolled
open-label 1 year
Industry sponsored
Serra,
Marchioretto,
2012,[18] Italy, n
= 30
Single centre,
crossover, ‘ONS
‘on’ vs ‘off’ (n =
29)
Chronic
migraine or
medication
overuse
headache
Refractory to
 2
prophylactic
medications
Included Successful trial
stimulation
(50% in the
number or
severity of
attacks)
required
Controlled open-
label 2 x 1 month
(no washout
period),
uncontrolled
open-label 1 year
Hospital-based, no
external funding
Slotty et al. 2014,
[31] Germany, n
= 8
Single centre,
crossover,
Suprathreshold vs
subthreshold vs
no stimulation (n =
8)
IHS criteria for
chronic
migraine
Treated with
ONS &
reported
>30% pain
relief for 3
months, on
stable
medication
Not described All patients
already had
good response
to ONS—see
‘Treatment
history’
Double-blind
(except
suprathreshold
stimulation), 3 x 1
week (no
washout period)
No external
funding
*The numbers of patients actually included in the analyses by study authors
ICHD-2: International Classiﬁcation of Headache Disorder 2nd edition, IHS: International Headache Society, ONS: occipital nerve stimulation.
doi:10.1371/journal.pone.0116786.t001
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management group [17], which could be regarded as an open-label control group given that
the patients were already refractory to medication management when entering the study. The
single-centre crossover RCT by Serra and Marchioretto was designed as an open-label study
with ONS switched on in one group and off in another group for a month. The two groups
were then crossed over for another month [18]. However, patients in the ‘off’ group could
switch their stimulation on if they had30% worsening in the number or severity of migraine
attacks, and they did so after an average of just under five days. All patients had their ONS
switched on after two months and continued to be followed up for ten further months. The
other single-centre crossover RCT [31] compared suprathreshold stimulation (stimulation that
was felt to be effective in reducing pain), subthreshold stimulation (stimulation with amplitude
just below perception) and no stimulation. Patients received each of the stimulation options for
one week in random order with no washout period between them. Patients and physicians
were not aware of treatment allocation but suprathreshold stimulation cannot be effectively
blinded. [31] The study included patients who had already had good response (>30% pain re-
lief) to ONS for at least three months. It was set out to assess the significance of paresthesia and
possible placebo effects of ONS rather than effectiveness and safety.
Stimulation trials were carried out in three RCTs [16, 18, 19]. Occipital nerve blocks and
intraoperative testing were performed in the fourth [17]. Successful trial stimulation or nerve
block was a criterion for permanent implantation and study enrolment in all studies except the
PRISM study. Trial stimulation was unsuccessful in between 3% to 11% of the patients
screened in the trials [17–19]. Patients in all studies were refractory to at least two prophylactic
medications. Those who experienced medication overuse were excluded in the ONSTIM study
[17]. Baseline migraine days per month were similar across the studies (between 20 to 23).
The seven case series included a total of 115 patients (Appendix D in S1 File) [32–36]. Dura-
tion of follow-up ranged from 1 to 79 months for individuals. Two of the case series included
patients enrolled in RCTs described above [33, 34]. Stimulation parameters for all included
studies are listed in Appendix E in S1 File.
Assessment of risk of bias
The results of the risk of bias assessment for included RCTs are summarised in Table 2. The as-
sessment for the PRISM study was hampered by the lack of full-text publication [16]. Of the
other two multicentre RCTs, the risk of bias was judged to be high for the ONSTIM study for
incomplete outcome data (15% dropout excluded from analysis in the ONS group compared to
6% in the sham group and 0% in the medication management group) and selective outcome re-
porting (data were not reported for several statistically non-significant results) [17]. The Silber-
stein et al. 2012 study was judged to be at low or unclear risk of bias [19], with the main
uncertainty related to the effectiveness of blinding. Given that achieving paresthesia is consid-
ered a prerequisite for treatment effectiveness and a requirement before permanent implemen-
tation and trial enrolment in most studies, it is perceivable that a genuine sham control would
be very difficult to attain. However, the success of blinding was not measured in any of the tri-
als. The single-centre crossover RCT by Serra and Marchioretto was considered to be subject to
high risk of bias in several domains due to lack of blinding, high level of contamination be-
tween groups and other issues related to crossover design [18]. Finally the other single-centre
crossover trial by Slotty and colleagues [31] was judged to be of low risk for potential biases re-
lated to blinding for the comparison between subthreshold stimulation and no stimulation but
of high risk of bias for comparisons against suprathreshold stimulation. The selection of pa-
tients (who had already had good response to ONS), short treatment duration and lack of
washout periods rendered it to be judged as unsuitable for the purpose of assessing the
Occipital Nerve Stimulation for Chronic Migraine
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effectiveness and safety of ONS for treating chronic migraine. Consequently, its findings are
used only to inform discussion concerning placebo effects.
Effectiveness
Outcomes from RCTs were reported in different formats and were of various completeness
(Appendix B in S1 File). Narrative and tabulated summaries are provided (see text below and
Table 3). Meta-analyses were performed for two outcomes (Figs. 2 and 3).
Days with prolonged (4 hours) moderate or severe headache. This outcome was re-
ported in three multi-centre RCTs [16, 17, 19]. Patients in the trials had between 19–22 days
with prolonged, moderate or severe headache per month at baseline. Those receiving sham
stimulation had a reduction of 2–4 days per month at three months compared to baseline.
Meta-analysis shows that ONS was associated with an additional mean reduction of 2.59 days
Table 2. Risk of bias assessment of included randomized controlled trials.
Bias domain Source of bias Lipton et al. 2009
(PRISM study) [16]
Saper et al. 2011
(ONSTIM
study) [17]
Silberstein
et al. 2012 [19]
Serra and
Marchioretto,
2012 [18]
Slotty et al. 2014 [31]
Selection
bias
Random sequence
generation
Unclear risk Low risk Low risk Unclear risk Low risk
Allocation concealment Unclear risk Low risk Low risk Unclear risk Low risk
Performance
bias
Blinding of participants Unclear risk Unclear risk (high
risk for medication
management
group)
Unclear risk High risk Low risk (high risk for
suprathreshold
stimulation)
Blinding of study
personnel
Unclear risk Unclear risk Unclear risk High risk Low risk
Detection
bias
Blinding of outcome
assessment: patient
reported outcomes
Unclear risk Unclear risk (high
risk for medication
management
group)
Unclear risk High risk Low risk (high risk for
suprathreshold
stimulation)
Blinding of outcome
assessment:
investigator assessed
outcomes
Low risk Low risk Low risk High risk Low risk
Attrition bias Incomplete outcome
data
Unclear risk High risk Low risk Low risk Low risk
Reporting
bias
Selective reporting Unclear risk High risk Unclear Low risk Low risk
Other bias Any other important
concerns about bias
not covered in the
other domains above
Based on conference
abstract with very
limited information;
manufacturer-
sponsored study
Manufacturer-
sponsored study
Manufacturer-
sponsored
study
High risk
(weakness related
to crossover design
—see below)
High risk (patients
already had good
treatment response;
lack of washout—see
below)
Measurement of
effectiveness of
blinding and/or
patients’ expectation of
treatment effectiveness
Not done Not done Not done Not done Not done
Crossover
design
Analysis of paired data Not applicable Not applicable Not applicable Not done Yes
Assessment of
carryover effects and/
or justiﬁcation of
washout period
Not applicable Not applicable Not applicable Not done Not done
doi:10.1371/journal.pone.0116786.t002
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per month (95% CI 0.91 to 4.27, I2 = 0%) compared with sham control. The results were con-
sistent across studies (Fig. 2).
Lipton et al. stated in their conference abstract that in a pre-specified subgroup analysis for
this outcome, a trend in favour of patients without medication overuse (ONS vs. sham, reduc-
tion of 5.9 vs. 2.6 migraine days/month) was observed compared with patients with medication
Table 3. Additional short-term effectiveness results from randomized controlled trials.
Outcome measures Saper et al. 2011
(ONSTIM study)(n = 67)
Silberstein et al. 2012 (n = 157) Serra & Marchioretto, 2012 (n = 30)
Headache
(migraine) days
Mean reduction in headache days
per month at 3 months:
Not reported Median headache days per week at 1 month
(before crossover):
ONS (n = 28): 6.7±10.0 ONS on: 2.1
Sham (n = 16): 1.5±4.6 (p = 0.02) ONS off: 6.3 (p<0.001)
Medication management (n = 17): 1.0
±4.2 (p = 0.008)
Headache
intensity*
Mean reduction in overall pain
intensity (0–10 scale) at 3 months:
Patient-reported percentage
headache pain relief at 3 months:
Median headache severity (0–10 scale) at 1
month:
ONS: 1.5±1.6 ONS (n = 105): 42% ONS on: 5
Sham: 0.5±1.3 (p = 0.02) Sham (n = 52): 17% (p<0.05) ONS off: 7.5 (p<0.001)
Medication management: 0.6 ±1.0 (p =
0.02)
MIDAS scores Mean change in MIDAS average
grade at 3 month:
Difference in mean reduction in
MIDAS scores at 3 months
Median MIDAS total score (interquartile
range), both groups combined** (n = 29):
ONS: 0.4±0.8 ONS vs. sham, 44.1, Baseline: 79 (30–135)
Sham: not reported 95% CI 22.8 to 65.3 3 months: 19 (0–44)
Medication management: 0.0 ±0.0 (p =
0.02)
(p = 0.001).
Utilization of acute
medication
Mean reduction in acute medication
use at 3 months:
Not reported Median monthly doses of triptans, both
groups combined** (n = 22):
ONS: 1.6±7.6 Baseline: 20; 3 months: 3
Sham: not reported Median monthly doses of NSAIDs,
Medication management: -0.6 ±5.0 (p =
0.24)
both groups combined** (n = 16)
Baseline: 25.5; 3 months: 3
MIDAS: Migraine Disability Assessment; NSAIDs: non-steriodal anti-inﬂammatory drugs; ONS: occipital nerve stimulation. Results from Lipton et al. 2009
(PRISM study, n = 140) were not published. P values shown are in comparison with the ONS group.
*Additional results (one-week treatment, n = 8) from Slotty et al. are described in Appendix S6 in S1 File.
**Comparative data not reported.
doi:10.1371/journal.pone.0116786.t003
Fig 2. Results of meta-analysis of RCT data for ONS compared with sham stimulation: days with prolonged (4 hours) moderate or severe
headache.
doi:10.1371/journal.pone.0116786.g002
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overuse (ONS vs. sham, reduction of 5.0 vs. 4.8 migraine days/month) [16]. However, results
for a formal test of interaction for the difference between subgroups were not presented.
Responder rate. The two studies that reported responder rates adopted a threshold of 50%
improvement but defined the outcome differently (see Appendix B in S1 File) [17, 19]. The
pooled result did not reach statistical significance and suggested a high level of heterogeneity
between the studies (ONS vs. sham control at 3 months, relative risk 2.07, 95% CI 0.50 to 8.55,
I2 = 51%; Fig. 3). Silberstein et al additionally conducted a continuous proportion responder
analysis, which showed that the difference between groups became significant when the thresh-
old of pain relief was reduced to 30% or lower (% responder 35% vs. 17% for ONS vs. sham
control, p = 0.02 using 30% pain relief as the threshold) [19].
Other effectiveness outcomes. Results for the reduction in headache (migraine) days,
headache intensity, Migraine Disability Assessment (MIDAS) scores and utilization of acute
medications are summarized in Table 3. Additional data on quality of life, satisfaction of treat-
ment and measures of physical and mental functions are described in Appendix F in S1 File.
While the results are significantly better in the ONS group compared to the control group for
the majority of outcomes, the reporting of results was incomplete and in some instances related
to the lack of statistical significance of the findings [17]. The observed sizes of effects also varied
widely for some of the outcomes. For example the difference in mean reduction in headache
days between ONS and sham control was approximately 5 days per month in the ONSTIM
study [17], but a much larger difference was reported in the open-label trial (median headache
day per week 2.1 vs. 6.3 for ONS vs. control respectively) [18].
Long-term effectiveness. One the three multicentre RCTs reported findings from long-
term follow-up beyond the initial blinded phase [30]. Additional long-term data ( one year)
were available from the single centre RCT by Serra & Marchioretto [18] and six of the case se-
ries [32–34, 36–38]. As patients in the control groups of the RCTs also received ONS after the
initial blinded phase, no long-term comparative data is available. The long-term effectiveness
results are summarised in Appendix G in S1 File. Overall, more than 80% of patients continued
to use ONS at 1 year across various studies, although the continuation rate seems to drop to
around 50–60% in case series with longer follow-up of varied duration. The short-term effec-
tiveness of ONS appears to be maintained in patients who stayed on the treatment.
Adverse events
Results from both RCTs and case series are presented here. Data from intervention and sham
control arms are combined within each RCT unless otherwise specified.
Serious adverse events. Serious adverse events occurred in between 1% (2/157) [19] to 6%
(3/56) [17] of patients in multicentre RCTs at 3 months. Forty of the 209 adverse events (19%)
recorded at 1 year in the trial by Silberstein et al. were classified as serious adverse events, of
Fig 3. Results of meta-analysis of RCT data for ONS compared with sham stimulation: response rate.
doi:10.1371/journal.pone.0116786.g003
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which 58% (23/40) were not considered as treatment-related and 35% (14/40) were related to
lack of efficacy or return of symptoms. Up to 20% (2/10) [33] of patients experienced serious ad-
verse events in smaller case series of varied duration of follow-up. Six out of nine patients (67%)
in the terminated UK PRISM trial experienced serious adverse events [39]. The majority of
treatment-related serious adverse events reported in these studies (except those related to lack of
efficacy) were associated with infection, lead migration, post-operative symptoms and psychiat-
ric complications (causality unclear). Further details are provided in Appendix F in S1 File.
Lead migration/dislodgement. Lead migration/dislodgement was common (Fig. 4). As
expected higher rates were seen in case series with longer follow-up. One case series [35] sug-
gests that using paddle-type leads rather than cylindrical leads can reduce the occurrence of
lead migration. Measures were instigated during the ONSTIM trial to reduce lead migration
[17], including the use of circular coils when placing the lead extension to create strain-relief
loops, and choosing the abdomen in preference of the buttock as the implant location for the
pulse generator. However, the impact of these measures was not formally assessed.
Infection. Reported infection rates range from 4% to 30% with varied length of follow-up
(Fig. 5). The exact infection rates were difficult to ascertain in some studies due to the different
ways in which infections were described and classified (see footnote for Fig. 5).
Other adverse events. Seventy-one percent (111/157) of patients experienced one or more
adverse events over one year in the RCT by Silberstein and colleagues. Of a total of 209 adverse
events recorded, 56 (27%) were hardware-related (e.g. battery failure, device malfunction or
disconnection etc.), 82 (39%) were ‘biological’ events (e.g. infection, skin erosion, pain, numb-
ness or swelling, allergic reaction, hematoma etc.), 45 (22%) were stimulation-related (e.g. un-
intended change in headache severity or stimulation, lack of efficacy, muscle spasms/cramping,
nausea/vomiting etc.) and the remaining 26 (12%) were not considered treatment-related.
Eighteen (9%) of the adverse events required hospitalization and 85 (41%) resulted in an addi-
tional surgery. Similar types of adverse events were reported in other RCTs and case series.
Long-term complications or potential nerve damage. Two trials reported that there was
no evidence of adverse device effects leading to long-term complications or potential nerve
damage (at three months [17] and one year [18] respectively). A case of subcutaneous tissue
change at implant site and another case of reduction or loss of musculoskeletal control were re-
ported in Silberstein et al [19].
Fig 4. Adverse effects associated with implantation and/or use of occipital nerve stimulation: lead
migrations.
doi:10.1371/journal.pone.0116786.g004
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Discussion
This systematic review examines current evidence for using ONS for chronic migraine. Com-
prehensive literature search was performed, which identified five RCTs and seven case series
that met the inclusion criteria. Findings from the RCTs suggest that at 3-month follow-up
ONS reduces the number of days with prolonged moderate/severe headache by approximately
2.5 days per month compared to sham stimulation (which in itself brings about a reduction of
2–4 days per month compared to baseline). Responder analysis at 3 months using a threshold
of 50% reduction in headache days and/or pain intensity favoured ONS but did not reach sta-
tistical significance in either individual trials or pooled results. ONS was shown to be more ef-
fective than sham control for other outcome measures, but results were often reported
incompletely and in different formats, hindering the analysis of evidence across studies. Overall
the level of evidence is considered moderate to low according to the GRADE framework [24]
(see Appendix H in S1 File for Summary of Findings Table).
The short-term results indicate that the effect of ONS is, on average, modest among patients
with chronic refractory migraine although the observed effects may still be clinically important
given the refractory nature of the condition. Some individual patients experienced significant
improvement that lasted for years in case series but the data is limited. On the other hand, ad-
verse events associated with the devices and surgical procedures including lead migration and
infections remain relatively common. These findings suggest that while ONS may be a valuable
option when patients have exhausted other non-invasive treatments, further improvement in
both efficacy and safety may be needed before it can firmly be established within the treatment
pathway. Further large reductions in pain are desired by patients and associated with improve-
ments in other outcomes including improved quality of life [40, 41]. To date the proportion of
patients who achieved a response (albeit short of “no worse than mild pain”) in the larger trials
has not been very high even at three months.
Fig 5. Adverse effects associated with implantation and/or use of occipital nerve stimulation:
infections. Saper 2011—the number shown was infections at site for lead/extension tract. There were
additionally four ‘complications at incision sites’.[17] Silberstein et al. 2012—there were additionally ‘wound
site complications’ (four at 3 months;[28] five at 1 year[30]). Lipton et al. described infections being the most
frequent device-related adverse events but did not report the numbers in their published abstract.[16] The
three cases described by Kiss and colleagues were ‘inflammation at surgical sites’ (3/10, 30%) that were
treated with intravenous and oral antibiotics.[33] They stated that ‘neither blood nor wound cultures identified
bacterial growth’.
doi:10.1371/journal.pone.0116786.g005
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The definition of chronic migraine has evolved over time and this is reflected in the varied
inclusion criteria for the RCTs included in our review. Whether the overall effectiveness of
ONS can be improved by refining diagnostic and patient selection criteria remains to be seen.
Limited evidence suggested that response to occipital nerve block may not be a useful predictor
for response to ONS treatment[42]. While a subgroup analysis from the PRISM trial [16] and a
small case series [43] suggested that ONS is more effective in patients without medication over-
use, the observed effectiveness was similar between the ONSTIM trial (which excluded patients
with medication overuse) and the other trials which allowed patients with medication overuse,
including the crossover trial by Serra and Marchioretto in which 85% of the patients with
chronic migraine also met the criteria for medication overuse [18].
A previous systematic review published in 2008 included only case series [15]. The identifi-
cation in the current review of five completed and an ongoing RCT [29] and registry [44] is en-
couraging. In particular, three of the completed RCTs were industry-sponsored multicentre
trials, which incorporated a sham control group with some attempts of blinding. The successful
completion of these trials exemplifies that assessment of interventional procedures need not
rely upon case series only. Despite this, the incomplete publication and reporting of results
from ONS trials is an ongoing concern, the existence of which goes against the current move-
ment of making all trial results available [45].
This systematic review has some limitations. Firstly, while the comprehensive search also at-
tempted to retrieve unpublished data, none was made available and therefore the review find-
ings are based upon published data only. Given the consistency in findings in the key outcome
(reduction in prolonged, moderate/severe headache) reported in the three larger RCTs, the po-
tential publication and reporting bias is likely to influence the estimation of effect sizes for
other incompletely reported outcomes rather than change the direction of effect. Secondly, de-
spite the existence of published guidelines for chronic migraine trials [22], the synthesis of evi-
dence was hindered by the different ways in which outcomes were selected and reported in
individual studies. Moreover, long-term data is limited. Apart from the one year results of the
RCT by Silberstein and colleagues[30], evidence is available from predominantly single-centre
case series, which could only provide imprecise estimations with uncertain generalizability.
An area of uncertainty for the RCT findings relates to how effective the blinding was in each
of the trials, and how much this influenced the observed results. Patients with refractory mi-
graine who are willing to try an invasive intervention are likely to have high expectations of the
efficacy of the intervention [46], and there is some evidence that differential expectation due to
presence or absence of blinding could impact upon observed clinical effects [47]. Apart from
attempts to directly measure the success of blinding, future trials also need to pay attention to
potential unblinding through patients’ sharing of experiences in social media as highlighted by
Goadsby [48].
Slotty and colleagues compared suprathreshold stimulation, subthreshold stimulation
(stimulation just below perception) and no stimulation in a small double-blind, crossover trial
of ONS responders [31]. Although the issue of blinding remains for the suprathreshod stimula-
tion, the observed differences in the reduction in pain intensity between each of the groups (see
Appendix F in S1 File) suggests that while paresthesia contributes to the analgesia, the effect of
ONS seems to go beyond merely a placebo effect induced by paresthesia.
In conclusion, currently evidence on the effectiveness and safety of ONS is still limited in
quantity and remains inconclusive given the challenges in trial methodology and patient selec-
tion. Further development of ONS and other similar techniques and validation of their efficacy
require both continuous accumulation of clinical evidence (for which multicentre, prospective
registries may have an important role to play) and further studies on the pathophysiology of mi-
graine and its responses to various forms of neuromodulation. In the interim, the use of ONS
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may be best guided by individual patient preference, affordability, treatment response and con-
tribution to the accumulation of the evidence base through RCTs or prospective registries [49].
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